{
    "2019-11-15": [
        [
            {
                "time": "2023-10-05",
                "original_text": "AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Merck",
                        "Selumetinib",
                        "NDA",
                        "FDA",
                        "Priority Status"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "4 Big Drugmakers to Bet on After a Great Earnings Season",
                "features": {
                    "keywords": [
                        "Big Drugmakers",
                        "Earnings Season"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}